Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1058 of 6351
-
Sound waves to the brain: a new hope for Alzheimer's?
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Sound waves vs. prostate cancer: a gentler approach?
Disease control CompletedThe aim of the focal treatment HIFU is to destroy the cancer without causing side effects in contrast to radical treatments. Radical treatments (surgery or radiation therapy) are the standard therapies for patient with intermediate risk localized prostate cancer and good life exp…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New PET scan technique could map hidden prostate cancer recurrences
Diagnosis CompletedThis study aims to institute a province-wide registry leveraging the availability of a new Positron Emission Tomography tracer, \[18F\]-DCFPyL and PET expertise across Ontario centers to improve our ability to characterize patterns of recurrence and personalize therapies in men w…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a simple scope procedure stop recurrent pancreatitis? SHARP trial results are in
Prevention CompletedThe purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy …
Sponsor: Oregon Health and Science University • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
Disease control OngoingThe objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulat…
Phase 1/2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New light therapy could zap skin cancer without surgery
Disease control OngoingThe aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).
Phase 3 • Sponsor: Biofrontera Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Precision proton beams take aim at High-Risk prostate tumors
Disease control OngoingThe purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer. The study features hypofractionation and a simultaneous integrated boost to the magnetic resonance imaging (MRI) identified intraprostat…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can treating the original tumor boost survival in advanced prostate cancer?
Disease control Recruiting nowThis phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surge…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
DNA vaccine shows promise against anal precancer in HIV patients
Disease control CompletedThis phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA…
Phase 2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
A monthly ring could put HIV prevention in Women's hands
Prevention OngoingParticipants will have a 28-day pre-ring baseline assessment period (Stage 1) followed by randomization to order with 5 participants per study arm. All participants will sequentially receive both study products for 28-days with at least a 2-week washout period between products. A…
Early phase 1 • Sponsor: Oak Crest Institute of Science • Aim: Prevention
Last updated Aug 28, 2026 00:00 UTC
-
New immunotherapy drug tislelizumab targets Hard-to-Treat cancers
Disease control Recruiting nowIn this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets tough leukemia in phase II trial
Disease control Recruiting nowThis phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cell…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New heart valve device offers hope for High-Risk patients
Disease control OngoingThis study will monitor the safety and valve performance of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for surgical aortic valve replacement (SAVR).
Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Poop pills may tame gut disease in major trial
Disease control OngoingUlcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. UC pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota (called dysbiosis) in predisposed hosts. The purpose of this study is to determi…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Blood marker may flag infants at risk for sudden death
Diagnosis Stopped earlyApparent Life-Threatening Events (ALTE) in infants often lead to severe neurological complications or to sudden death. In such situations, cardio-pediatricians and intensive care physicians have no specific diagnosis or treatment. In a recent translational research (INSERM-DHOS),…
Sponsor: University Hospital, Strasbourg, France • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancer
Disease control CompletedBackground: Multiple myeloma is a cancer of the blood plasma cells. It usually becomes resistant to standard treatments. Researchers have developed a procedure called gene therapy. It uses a person's own T cells, which are part of the immune system. The cells are changed in a la…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Two-Drug cocktail targets Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (c…
Phase 1/2 • Sponsor: Veronika Bachanova • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a Brain-Cancer drug take on a stubborn stomach tumor?
Disease control CompletedFunding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib. Although there are FDA-approved products for the treatment of advanced/metastatic GIST, these therapies are known to be ineffective…
Phase 2 • Sponsor: Adam Burgoyne, MD, PhD • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC